Aurobindo receives FDA approval for Adenosine Injection Single-Dose Vials!
On November 02, 2017 Aurobindo received FDA approval for Adenosine Injection Single-Dose Vials which is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately. With an estimated total annual market of $17.3 million through June 2017 according to IMS data, this is an exciting addition to the AuroMedics portfolio.[...] Read more
Aurobindo receives FDA approval for Lidocaine HCl Injection Multiple-Dose Vials!
On October 30, 2017 Aurobindo received FDA approval for Lidocaine HCl Injection Multiple-Dose Vials. AuroMedics currently markets the Single-Dose Vials and looks forward to the growth of this product family. This product has an estimated annual market size of $39.5 million through June 2017 according to IMS data. [...] Read more
Aurobindo receives FDA approval for Amiodarone HCl Injection!
On October 25, 2017 Aurobindo received FDA approval for Amiodarone HCl Injection which is an antiarrhythmic indicated as the initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation (and hemodynamically unstable ventricular tachycardia) in patients refractory to other therapy. According to IMS data annual reporting through June 2017, the market size of this product is[...] Read more
Take a look at our breathtaking new distribution center!
AuroMedics could not be more excited to announce the opening of our brand new, state of the art facility located right in our headquarter’s backyard. Get the details and take a virtual tour by clicking the link below. Aurobindo opens new state of the art, fully automated, distribution center spanning across 59 acres of land[...] Read more